The «Import-Substituting Production of Genetically Engineered and Analog Insulin from Proprietary Substance project» has been under way since 2016 and supported by the Industry Development Fund of the Russian Federation.

The «Medsintez» plant plans to manufacture substances of genetically engineered and analog insulin (Aspart, Glargin) for subsequent use in its own production of finished dosage forms.

The implementation of the project will allow to give up purchasing foreign substances and create a full-cycle insulin production. The domestic production of the substances will help reduce prices for finished insulin by 15-20% relative to import prices. The insulins will be produced in the most convenient and familiar finished dosage forms for patients: in cartridges and syringe pens.

For the project, the following have been created at the «Medsintez» plant:

A modern R&D lab for genetics and biotechnology (2014)

A pilot zone (for developing a technology for the production of genetically engineered drugs, including the substance of analog insulin forms) (2015)

The planned production capacity for the substance of genetically engineered human insulin is up to 400 kg annually.